相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives
Alexandra Lucaciu et al.
CELLS (2020)
Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article
Stanley Cohan et al.
BIOMEDICINES (2020)
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
Jeffrey A. Cohen et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
Newshan Behrangi et al.
CELLS (2019)
Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
Jeffrey A. Cohen et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
An update on sphingosine-1-phosphate receptor 1 modulators
Alexander Marciniak et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk
Kunio Sugahara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Natalizumab-associated PML Challenges with incidence, resulting risk, and risk stratification
Nicholas Schwab et al.
NEUROLOGY (2017)
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
Burhan Z. Chaudhry et al.
NEUROTHERAPEUTICS (2017)
Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation
Veit Rothhammer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
Nicola De Stefano et al.
CNS DRUGS (2017)
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
Jeffrey A. Cohen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
Antonietta Gentile et al.
JOURNAL OF NEUROINFLAMMATION (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2016)
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2016)
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study
Ludwig Kappos et al.
JAMA NEUROLOGY (2016)
Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases
Daniele D'Ambrosio et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2016)
Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm
Sonja Kroesser et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Long-term effects of fingolimod in multiple sclerosis The randomized FREEDOMS extension trial
Ludwig Kappos et al.
NEUROLOGY (2015)
Sphingosine 1-phosphate signaling at the blood-brain barrier
Briana Prager et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod Risk Assessment and Consensus Recommendations for Management
Ann M. Arvin et al.
JAMA NEUROLOGY (2015)
Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications
John Camm et al.
AMERICAN HEART JOURNAL (2014)
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
Alice Laroni et al.
BMC NEUROLOGY (2014)
New management algorithms in multiple sclerosis
Per Soelberg Sorensen
CURRENT OPINION IN NEUROLOGY (2014)
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
Tomas Olsson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
G. Francis et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
Goeril Karlsson et al.
NEUROLOGY (2014)
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies
John P. DiMarco et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study
Patrick Brossard et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis
T. Komiya et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients
Andrew J. Fine et al.
CLINICAL INFECTIOUS DISEASES (2013)
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Krzysztof Selmaj et al.
LANCET NEUROLOGY (2013)
Prolonged and symptomatic bradycardia following a single dose of fingolimod
Hans Faber et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
T-cell response against varicella-zoster virus in fingolimod-treated MS patients
Meret E. Ricklin et al.
NEUROLOGY (2013)
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis
Marco A. Zarbin et al.
OPHTHALMOLOGY (2013)
Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator
Shifeng Pan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
P. Gergely et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Clinical Pharmacokinetics of Fingolimod
Olivier J. David et al.
CLINICAL PHARMACOKINETICS (2012)
Sudden unexpected death on fingolimod
J. W. Lindsey et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Fingolimod-associated macular edema Incidence, detection, and management
Nieraj Jain et al.
NEUROLOGY (2012)
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
Bhupendra Khatri et al.
LANCET NEUROLOGY (2011)
Delayed fingolimod-associated asystole
Patricio S. Espinosa et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Impact of sphingosine 1-phosphate modulation on immune outcomes
Daniel D. Pinschewer et al.
NEUROLOGY (2011)
Sphingosine 1-phosphate (S1P) Physiology and the effects of S1P receptor modulation
Timothy Hla et al.
NEUROLOGY (2011)
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
M. Mehling et al.
NEUROLOGY (2011)
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Volker Brinkmann et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
M. Mehling et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lymph node cortical sinus organization and relationship to lymphocyte egress dynamics and antigen exposure
Irina L. Grigorova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage
Carolyn A. Foster et al.
BRAIN PATHOLOGY (2009)
FTY720 modulates human oligodendrocyte progenitor process extension and survival
Veronique E. Miron et al.
ANNALS OF NEUROLOGY (2008)
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate
Krishnan Venkataraman et al.
CIRCULATION RESEARCH (2008)
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
M. Mehling et al.
NEUROLOGY (2008)
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis
Carolyn A. Foster et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors
Rochelle P. Coelho et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis
Balazs Balatoni et al.
BRAIN RESEARCH BULLETIN (2007)
Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
Volker Brinkmann
PHARMACOLOGY & THERAPEUTICS (2007)
Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration
Alexander S. Novgorodov et al.
FASEB JOURNAL (2007)
Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate
Rajita Pappu et al.
SCIENCE (2007)
Phylogenetic classification of Cordyceps and the clavicipitaceous fungi
Gi-Ho Sung et al.
STUDIES IN MYCOLOGY (2007)
Effects of LPA and SIP on the nervous system and implications for their involvement in disease
D. R. Herr et al.
CURRENT DRUG TARGETS (2007)
Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3
M Tölle et al.
CIRCULATION RESEARCH (2005)
The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel IKACh
L Koyrakh et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival
C Jaillard et al.
JOURNAL OF NEUROSCIENCE (2005)
Expression of CCR7 in multiple sclerosis:: Implications for CNS immunity
P Kivisäkk et al.
ANNALS OF NEUROLOGY (2004)
Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes
M Forrest et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)
FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function
V Brinkmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Chemoattractants and their receptors in homeostasis and inflammation
F Sallusto et al.
CURRENT OPINION IN IMMUNOLOGY (2004)
Constitutive expression of the SlP(1) receptor in adult tissues
SS Chae et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2004)
Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells
M Graeler et al.
FASEB JOURNAL (2002)
Cell type-specific localization of human cardiac S1P receptors
D Mazurais et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2002)
Antiproliferative properties of sphingosine-1-phosphate in human hepatic myofibroblasts
A Pébay et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2001)
Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells
M Morales-Ruiz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory
DD Pinschewer et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
